- Home
- AVTX
as 12-23-2024 4:00pm EST
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 90.9M | IPO Year: | 2015 |
| Target Price: | $33.00 | AVG Volume (30 days): | 141.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -75.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.95 - $34.46 | Next Earning Date: | 11-07-2024 |
| Revenue: | $820,000 | Revenue Growth: | -63.54% |
| Revenue Growth (this year): | -88.1% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Avalo Therapeutics Inc. (AVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Almenoff June Sherie | AVTX | Director | Nov 12 '24 | Buy | $12.75 | 1,000 | $12,749.50 | 500 |
Latest Avalo Therapeutics Inc. News
AVTX Breaking Stock News: Dive into AVTX Ticker-Specific Updates for Smart Investing
TipRanks
4 days ago
Avalo Therapeutics initiated with a Buy at BTIG
GlobeNewswire
a month ago
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
GlobeNewswire
a month ago
Avalo Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
2 months ago
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
GlobeNewswire
3 months ago
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
GlobeNewswire
4 months ago
Avalo Announces Participation in September Investor Conferences
GlobeNewswire
4 months ago
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
5 months ago
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
Compare AVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVTX Avalo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.